NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
GREENCanagliflozin
(For patients with Type 2 diabetes) 		Endocrine system, SGLT2 inhibitors, 06.01.02.03
 Canagliflozin
(For Chronic kidney disease WITH Type 2 diabetes) 		Obstetrics, Gynaecology, and urinary-tract disorders, Other preparations for urinary disorders, 07.04.03
GREENErtugliflozin Steglatro®
(For patients with Type 2 diabetes) 		Endocrine system, SGLT2 inhibitors, 06.01.02.03
Non Formulary items found
Status Description Section
 Canagliflozin / metformin IR Vokanamet® Endocrine system, Other antidiabetic drugs, 06.01.02.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Canagliflozin Canagliflozin Endocrine System, Blood Glucose Lowering Drugs, Sodium Glucose Co-Transporter 2 Inhibitors
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Canagliflozin Canagliflozin With Metformin Endocrine System, Blood Glucose Lowering Drugs, Biguanides
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Canagliflozin Canagliflozin With Metformin Endocrine System, Blood Glucose Lowering Drugs, Sodium Glucose Co-Transporter 2 Inhibitors
Diabetes Mellitus And Hypoglycaemia, Diabetes Mellitus
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
MHRA Drug Safety Update (June 2016) - Canagliflozin (Invokana▼, Vokanamet▼): signal of increased risk of lower extremity amputations observed in trial in high cardiovascular risk patients
NICE TA1137: Canagliflozin for treating type 2 diabetes in people 10 to 17 years (TERMINATED APPRAISAL)
NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes